Search results
Results from the WOW.Com Content Network
Radioactive iodine (iodine-131) alone can potentially worsen thyrotoxicosis in the first few days after treatment. One side effect of treatment is an initial period of a few days of increased hyperthyroid symptoms. This occurs because when the radioactive iodine destroys the thyroid cells, they can release thyroid hormone into the blood stream.
The patient swallows a radioisotope of iodine in the form of capsule or fluid, and the absorption (uptake) of this radiotracer by the thyroid is studied after 4–6 hours and after 24 hours with the aid of a scintillation counter. The dose is typically 0.15–0.37 MBq (4–10 μCi) of 131 I iodide, or 3.7–7.4 MBq (100–200 μCi) of 123 I ...
Before then hand-held detectors had been used to locate radioactive materials in patients, but the Cassen system (designed for Iodine-131) combined a motor driven photomultiplier tube and printing mechanism. [2] [4] Subsequent developments improved the detection systems, movement, display and printing of images. [5] [6]
The test was first introduced in 1956, using iodine-131 diodrast. [25] [26] Later developments included iodine-131, and then iodine-123, labelled ortho-Iodohippuric acid (OIH, marketed as Hippuran). [27] [28] 99m Tc-MAG3 has replaced 131 I-OIH because of better quality imaging regardless of the level of kidney function, [29] and lower radiation ...
The uptake test involves administering a dose of radioactive iodine (radioiodine), traditionally iodine-131 (131 I), and more recently iodine-123 (123 I). Iodine-123 may be the preferred radionuclide in some clinics due to its more favorable radiation dosimetry (i.e. less radiation dose to the person per unit administered radioactivity) and a ...
Often called the father of nuclear medicine, Lawrence treated a leukemia patient with radiophosphorus, which was the first time a radioactive isotope has been used to treat human patients. [4] Another pioneer in the field, Sam Seidlin, in partnership with Saul Hertz, treated a case of thyroid cancer with radioactive iodine (I-131) 1946. [5]
Iodinated contrast contains iodine.It is the main type of radiocontrast used for intravenous administration.Iodine has a particular advantage as a contrast agent for radiography because its innermost electron ("k-shell") binding energy is 33.2 keV, similar to the average energy of x-rays used in diagnostic radiography.
Contrast CT of a patient with brain metastases from breast cancer, before (left) and after (right) injection of iodinated contrast.. Iodinated contrast is a form of water-soluble, intravenous radiocontrast agent containing iodine, which enhances the visibility of vascular structures and organs during radiographic procedures.